Jiawei Chen’s research while affiliated with Zhejiang Chinese Medical University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (4)


Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2/STAT3/SOCS1 pathway in streptozotocin-induced diabetic rats
  • Article

January 2021

·

16 Reads

·

56 Citations

Life Sciences

Maolin Zhu

·

Huiyang Wang

·

Jiawei Chen

·

Huang Zhu

Aims To investigate the therapeutic effects and potent mechanism of sinomenine (SIN) nanoliposomes on nephropathy in diabetic rats. Main methods The protective efficacies of SIN on the oxidative injury in renal HK-2 cell induced by hydrogen peroxide (H2O2) were investigated via the CCK-8 assay. Forty SD rats with streptozotocin (STZ)-induced diabetic kidney disease (DKD) were assigned to the saline group and three SIN groups (10, 20 and 40 mg/kg). During 6-week treatment, body weight, fasting glucose level and other metabolic parameters were recorded. H&E staining and changes in renal functions as well as expression levels of apoptosis and fibrosis-related factors in renal tissues were assessed. The qPCR and western blotting (WB) methods were used to detect relative expression levels of JAK/STAT/SOCS pathway-related factors in the renal tissues. Key findings Cell viabilities of HK-2 cells with oxidative injury were obviously improved by incubating with SIN at 320 μg/mL for 92.9%. Significantly up-regulated GPX1, SOD2 and GSH contributed to the down-regulated ROS content in SIN-treated groups. Moreover, 6-week administration of SIN improved renal functions and worsening nephropathy morphology of DKD rats. SIN also ameliorated gradually increased renal cell apoptosis, suppressed expression levels of fibrosis-related proteins as well as IL-6 and ICAM-1, and regulated JAK2/STAT3/SOCS1 pathway, thereby exhibited protective effects on renal tissues of DKD rats. Conclusion SIN protects nephrocytes and decreases renal tissue injury via inhibiting oxidative stress, reducing renal cell apoptosis and fibrosis, regulating the JAK2/STAT3/SOCS1 pathway in DKD rats.


Amygdalin alleviates renal injury by suppressing inflammation, oxidative stress and fibrosis in streptozotocin-induced diabetic rats

January 2021

·

17 Reads

·

39 Citations

Life Sciences

Jiawei Chen

·

Yongbin Hu

·

Xin Mou

·

[...]

·

Zhujuan Xie

Aims To explore the protective efficacies and potent mechanism of amygdalin on high glucose-cultured renal cell HBZY-1 in vitro and streptozotocin (STZ)-induced diabetic nephropathy (DN) rat in vivo. Main methods The cellar proliferation and generation of ROS in high-glucose cultured HBZY-1 cell were assessed by MTT and DCFH-DA assay, respectively. The fasting blood glucose levels, renal function and inflammation indexes as well as oxidative stress markers in STZ-induced diabetic rats were all measured. The histologic renal section was stained with Mason and periodic acid-Schiff (PAS) method. Immunohistochemistry and western blotting methods were applied to assess expression levels of extracellular matrix (ECM), epithelial-mesenchymal transition (EMT)-related as well as TGF-β1/Smad signaling pathway-related proteins. Key findings Firstly, amygdalin significantly suppressed the excessive cell proliferation and ROS generation in HBZY-1 cells cultured with high glucose. The hyperglycemia, 24 h-UP excretion, BUN and Scr of DN rats were significantly attenuated after the chronic treatment of amygdalin. Moreover, MDA, SOD, IFN-γ and IL-12 levels in kidney tissues were all effectively reduced. Besides, amygdalin can suppress the ECM accumulation and EMT transformation by inhibiting Smad/TGF-β pathway to alleviate the renal fibrosis in renal tissues of DN model rats. Significance Amygdalin ameliorates excessive oxidative stress, inflammation and renal tissue fibrosis of DN mainly by suppressing TGF-β1/Smad signaling pathway and regulating the key enzymes of ECM degradation.


Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals

January 2021

·

4 Reads

·

2 Citations

Life Sciences

Objective Glucose-dependent insulinotropic polypeptide receptor (GIPR) has been identified as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO). Therefore, we developed the anti-GIPR antagonistic monoclonal antibody (mAb) alone and in combination with DPP-4 inhibitor as potential therapeutic strategy for treating obesity and dyslipidemia based on this genetic evidence. Methods Fully neutralized GIPR activity of GIPR-monoclonal antibody (mAb) was assessed by regulating the in vitro production of cAMP in the mouse GIPR stably expressing cells. Chronic efficacies of GIPR-mAb alone and in combination with DPP-4 inhibitor Sitagliptin in diabetic or DIO mice were both investigated. Multiple metabolic parameters including body weight, glucose level, fat mass, lipid metabolism-related indicators as well as H&E staining and immunohistochemical analysis were performed. Role of GIPR in pancreatic cells on regulating fat metabolism was explored in GIPR β-cell knockout mouse model. Results Chronic treatment of GIPR-mAb improved body weight control, glucose metabolism, and was associated with reduced fat mass, enhanced pancreatic function and exchange ratio of the resting respiratory in diabetic mice. In addition, further study of anti-GIPR mAb combined with Sitagliptin in DIO mice demonstrated significantly improved weight loss compare to the both monomer treatment. Furthermore, we demonstrated important role of GIPR in β-cell in regulating the fat mass and response to antagonistic GIPR-mAb in a conditional GIPR-knockout mouse. Conclusion Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor provide preclinical therapeutic approaches to treat obesity.


FIGURE 1 | Receiver operating characteristic (ROC) curve for the discrimination of patients with Graves' disease from healthy controls and patients with subacute thyroiditis. *The detailed indicator combination formula is presented in the text. Eo, eosinophils; fT 3 , free triiodothyronine; fT 4 , free thyroxine; Mo, monocytes.
Clinical characteristics of the study population.
Diagnostic evaluation of cut-off levels of various indexes in untreated Graves' disease.
Positive value and likelihood ratio of cut-off levels of various indexes in untreated Graves' disease.
Eosinophil/Monocyte Ratio Combined With Serum Thyroid Hormone for Distinguishing Graves' Disease and Subacute Thyroiditis
  • Article
  • Full-text available

May 2020

·

152 Reads

·

10 Citations

Background: Thyrotoxicosis is commonly classified into several entities according to different etiologies. Identifying the causes of thyroid dysfunction is critical for the subsequent selection of treatment. The free triiodothyronine to free thyroxine ratio (fT3/fT4) is widely used but is still a controversial diagnostic measurement. Methods: A total of 290 patients including 141 healthy control subjects, 86 patients with untreated Graves' disease (GD,) and 63 patients with subacute thyroiditis (SAT) were enrolled in the study. The main aim was to evaluate the diagnostic value of different indexes from serum testing including fT3, fT4, eosinophils (Eo) and monocytes (Mo). The diagnostic performance of multiple indexes was evaluated separately using receiver operating characteristic curve analysis. Results: Sensitivities and specificities of fT4/fT3, Mo/Eo ratios and Mo/Eo ratio + fT4/fT3 for diagnosing GD were 80.23 and 88.89, 82.56 and 60.32, and 74.4 and 87.3 with cut-off values of ≤ 2.841, ≤ 8.813 and >0.644, respectively. An equation of combined indicators including Mo, Eo, fT3, and fT4 data was developed to calculate a probability value and among all indexes studied the indicator combination formula gave the best diagnostic value, reaching sensitivity and specificity of 89.53 and 90.48%, respectively, with an optimum cut-off value at 0.561 for GD diagnosis. Conclusion: Compared to regular indexes (fT4/fT3 and Mo/Eo), a newly developed indicator combination formula provided a higher prediction probability and may serve as a simple, cost-effective tool for differentiating GD from SAT patients, especially in undeveloped regions of China.

Download

Citations (4)


... Thus, the partial GIPR antagonist, (Pro 3 )GIP, has originally been demonstrated to improve obesity-related diabetes, reducing islet hypertrophy and improving insulin sensitivity [122], while also eliciting 8% weight loss following administration alone in obese mice [123]. These observations have been largely confirmed by others employing GIPR monoclonal antibodies [124]. Interestingly, there is a suggestion that the metabolic benefits of chronic GIPR agonism are related to desensitization of the GIPR, thus mimicking GIPR antagonism [125]. ...

Reference:

GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals
  • Citing Article
  • January 2021

Life Sciences

... [12][13][14][15] Recent study found that amygdalin ameliorates renal and liver fibrosis mainly by suppressing TGF-β1/Smad signaling pathway and regulating the key enzymes of ECM degradation -Matrix Metalloproteinases-9 (MMP-9) and tissue Inhibitor of Metalloproteinases 1 (TIMP-1). 16,17 In addition, as an active ingredient of Fuzheng Huayu formula, which is a NMPA (National Medical Products Administration)-approved anti-fibrotic medicine in China, amygdalin is effective at alleviating liver fibrogenesis by inhibiting the proliferation and collagen production of active HSC, HSC activation and hepatocyte apoptosis. [18][19][20][21][22][23][24] However, due to the herbal products having multi-modulatory and multi-target action, comprehensive mechanism of anti-fibrotic effects of amygdalin remains elusive. ...

Amygdalin alleviates renal injury by suppressing inflammation, oxidative stress and fibrosis in streptozotocin-induced diabetic rats
  • Citing Article
  • January 2021

Life Sciences

... Additionally, Ruxolitinib and Nifuroxazide, which inhibit the JAK/STAT pathway, have shown promise in experimental models for DKD treatment by reducing fibrosis and inflammation [149,150]. Natural products like Sinomenine, Silymarin and Paeoniflorin have also been studied for their ability to modulate the JAK/STAT pathway and offer potential therapeutic benefits for DKD [151,152]. Other medications, such as liraglutide and vitamin D, have been found to inhibit the JAK/STAT pathway and alleviate DKD-related inflammation and fibrosis, although further clinical trials are needed to confirm their long-term efficacy and safety [153,154]. ...

Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2/STAT3/SOCS1 pathway in streptozotocin-induced diabetic rats
  • Citing Article
  • January 2021

Life Sciences

... An unexpected finding was the significant decrease in eosinophils in the TT group. There is some evidence suggesting that the eosinophil count and eosinophil/monocyte indices can serve as an alternative marker to differentiate between DT and autoimmune hyperthyroidism (36,37). More specifically, an elevated eosinophil level is associated with Graves' disease while a low eosinophil/monocyte index ratio suggests DT. ...

Eosinophil/Monocyte Ratio Combined With Serum Thyroid Hormone for Distinguishing Graves' Disease and Subacute Thyroiditis